Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
 
Search Article 
  
Advanced search 
  Users Online: 8240 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  
This article has been cited by
1Review of Ongoing Activities and Challenges to Improve the Care of Patients With Type 2 Diabetes Across Africa and the Implications for the Future
Brian Godman,Debashis Basu,Yogan Pillay,Julius C. Mwita,Godfrey Mutashambara Rwegerera,Bene D. Anand Paramadhas,Celda Tiroyakgosi,Patrick Mbah Okwen,Loveline Lum Niba,Justice Nonvignon,Israel Sefah,Margaret Oluka,Anastasia N. Guantai,Dan Kibuule,Francis Kalemeera,Mwangana Mubita,Joseph Fadare,Olayinka O. Ogunleye,Larry A. Distiller,Enos M. Rampamba,Jeffrey Wing,Debjani Mueller,Abubakr Alfadl,Adefolarin A. Amu,Zinhle Matsebula,Aubrey Kalungia,Trust Zaranyika,Nyasha Masuka,Janney Wale,Ruaraidh Hill,Amanj Kurdi,Angela Timoney,Stephen Campbell,Johanna C. Meyer
Frontiers in Pharmacology.2020;11()
[DOI]
2Type II diabetes mellitus: a review on recent drug based therapeutics
Santwana Padhi,Amit Kumar Nayak,Anindita Behera
Biomedicine & Pharmacotherapy.2020;131()110708
[DOI]
3Effect of amodiaquine on the pharmacokinetics of gliclazide in diabetic subjects
Godwin Ishaku Sambo,Taibat Bakare-Odunola Mojirade,Musa Aminu,Adamu Yakasai Ibrahim,Garba Magaji,Adzu Bulus
African Journal of Pharmacy and Pharmacology.2019;13(11)139
[DOI]
4Unravelling the utility of modern sulfonylureas from cardiovascular outcome trials and landmark trials: expert opinion from an international panel
S. Kalra,S. Ghosh,A.K. Das,T. Nair,S. Bajaj,G. Priya,R.N. Mehrotra,S. Das,P. Shah,V. Deshmukh,M. Chawla,D. Sanyal,S. Chandrasekaran,D. Khandelwal,A. Joshi,F. Eliana,H. Permana,M.D. Fariduddin,P.K. Shrestha,D. Shrestha,S. Kahandawa,M. Sumanathilaka,A. Shaheed,A.A. Rahim,A. Orabi,A. Al-ani,W. Hussein,D. Kumar,K. Shaikh
Indian Heart Journal.2020;72(1)7
[DOI]
5Glucodynamics and glucocracy in type 2 diabetes mellitus: clinical evidence and practice-based opinion on modern sulfonylurea use, from an International Expert Group (South Asia, Middle East & Africa) via modified Delphi method
Sanjay Kalra,Das A. K.,Fariduddin Md.,Shaikh K.,Shah P.,Rehim A. A.,John M.,Shaikh S.,Orabi A.,Saraswati M. R.,Shahjada Selim,Baruah M. P.,K. K. Gangopadhyay,Langi Y. A.,Nair T.,Dhanwal D.,Thapa S. D.,Deshmukh V.,D. Dutta,Khalfan H.,Maskey R.,Das S.,Dasgupta A.,Bajaj A.,Priya G.,Chandrasekaran S.,A. Dhingra,Pandey N,Al Ani A.,Moosa M.
Current Medical Research and Opinion.2021;37(3)403
[DOI]
6Existe-t-il encore une place pour les sulfamides hypoglycémiants dans le traitement du diabète de type 2 en 2021 ?
André J. Scheen
Médecine des Maladies Métaboliques.2021;15(1)45
[DOI]
7The Position of Gliclazide in the Evolving Landscapes and Disease Continuum of T2DM: A Collaborative Delphi Survey-Based Consensus from India
Sanjay Kalra,A. G. Unnikrishnan,Ganapathi Bantwal,Sambit Das,Nareen Krishna Polavarapu,Kumar Gaurav
Diabetes Therapy.2021;12(3)679
[DOI]
8Prescription of Sulphonylureas among Patients with Type 2 Diabetes Mellitus in Italy: Results from the Retrospective, Observational Multicentre Cross-Sectional SUSCIPE (Sulphonyl_UreaS_Correct_Internal_Prescription_Evaluation) Study
Carlo Bruno Giorda,Emanuela Orsi,Salvatore De Cosmo,Antonio Carlo Bossi,Catia Guerzoni,Stefania Cercone,Barbara Gilio,Franco Cavalot
Diabetes Therapy.2020;11(9)2105
[DOI]
9Neuromodulatory effects of anti-diabetes medications: A mechanistic review
Habib Yaribeygi,Milad Ashrafizadeh,Neil C. Henney,Thozhukat Sathyapalan,Tannaz Jamialahmadi,Amirhossein Sahebkar
Pharmacological Research.2020;152(9)104611
[DOI]
10Modern Sulfonylureas Strike Back – Exploring the Freedom of Flexibility
Sanjay Kalra,Deepak Khandelwal
European Endocrinology.2018;14(2)20
[DOI]
11An update on the safety and efficacy of oral antidiabetic drugs: DPP-4 inhibitors and SGLT-2 inhibitors
Elizabeth Mary Lamos,Maka Hedrington,Stephen N Davis
Expert Opinion on Drug Safety.2019;18(8)691
[DOI]
12Sulfonylureas at the Glomerular Battlefield
Sanjay Kalra,Deepak Khandelwal,Sarita Bajaj,Ashok Kumar Das
European Endocrinology.2018;14(2)15
[DOI]
13Safety of lixisenatide versus sulfonylurea added to basal insulin treatment in people with type 2 diabetes mellitus who elect to fast during Ramadan (LixiRam): An international, randomized, open-label trial
Mohamed M. Hassanein,Rakesh Sahay,Khadija Hafidh,Khier Djaballah,Haoyu Li,Sami Azar,Naim Shehadeh,Wasim Hanif
Diabetes Research and Clinical Practice.2019;150(2)331
[DOI]
14Diabetes education in pediatrics: How to survive diabetes
Berrin Ergun-Longmire,Ethel Clemente,Patricia Vining-Maravolo,Cheryl Roberts,Koby Buth,Donald E. Greydanus
Disease-a-Month.2021;67(8)101153
[DOI]
15Glucocrinology of Modern Sulfonylureas: Clinical Evidence and Practice-Based Opinion from an International Expert Group
Sanjay Kalra,A. K. Das,M. P. Baruah,A. G. Unnikrishnan,Arundhati Dasgupta,Parag Shah,Rakesh Sahay,Rishi Shukla,Sambit Das,Mangesh Tiwaskar,G. Vijayakumar,Manoj Chawla,Fatimah Eliana,Ketut Suastika,Abbas Orabi,Aly Ahmed Abdul Rahim,Andrew Uloko,Silver Bahendeka,Abdurezak Ahmed Abdela,Fariduddin Mohammed,Faruque Pathan,Muhammed Hafizur Rahman,Faria Afsana,Shajada Selim,Muaz Moosa,Moosa Murad,Pradeep Krishna Shreshtha,Dina Shreshtha,Mimi Giri,Wiam Hussain,Ahmed Al-Ani,Kaushik Ramaiya,Surender Singh,Syed Abbas Raza,Than Than Aye,Chaminda Garusinghe,Dimuthu Muthukuda,Muditha Weerakkody,Shyaminda Kahandawa,Charlotte Bavuma,Sundeep Ruder,Koy Vanny,Manish Khanolkar,Leszek Czupryniak
Diabetes Therapy.2019;10(5)1577
[DOI]
16Treatment strategies against diabetes: Success so far and challenges ahead
Rubiya Khursheed,Sachin Kumar Singh,Sheetu Wadhwa,Bhupinder Kapoor,Monica Gulati,Rajan Kumar,Arya Kadukkattil Ramanunny,Ankit Awasthi,Kamal Dua
European Journal of Pharmacology.2019;862(5)172625
[DOI]
17Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: Expert opinion from a European consensus panel
Agostino Consoli,Leszek Czupryniak,Rui Duarte,György Jermendy,Alexandra Kautzky-Willer,Chantal Mathieu,Miguel Melo,Ofri Mosenzon,Frank Nobels,Nikolaos Papanas,Gabriela Roman,Oliver Schnell,Alexis Sotiropoulos,Coen D. A. Stehouwer,Cees J. Tack,Vincent Woo,Gian Paolo Fadini,Itamar Raz
Diabetes, Obesity and Metabolism.2020;22(10)1705
[DOI]
18Role of Gliclazide in safely navigating type 2 diabetes mellitus patients towards euglycemia: Expert opinion from India
Subhash Wangnoo,M. Shunmugavelu,Sagili Vijaya Bhaskar Reddy,Vijay Negalur,Shreerang Godbole,Vinay K Dhandhania,Nareen Krishna,Kumar Gaurav
Endocrine and Metabolic Science.2021;4(10)100102
[DOI]
19The Standard of Care in Type 2 Diabetes: Re-evaluating the Treatment Paradigm
Viswanathan Mohan,Mark E. Cooper,David R. Matthews,Kamlesh Khunti
Diabetes Therapy.2019;10(S1)1
[DOI]
20Conventional and Unconventional Mechanisms by which Exocytosis Proteins Oversee ß-cell Function and Protection
Diti Chatterjee Bhowmick,Miwon Ahn,Eunjin Oh,Rajakrishnan Veluthakal,Debbie C. Thurmond
International Journal of Molecular Sciences.2021;22(4)1833
[DOI]
21Sulphonylureas in the management of type 2 diabetes: To be or not to be?
André J. Scheen
Diabetes Epidemiology and Management.2021;1(4)100002
[DOI]
22Effect of insulin secretagogues on major cardiovascular events and all-cause mortality: A meta-analysis of randomized controlled trials
Edoardo Mannucci,Matteo Monami,Riccardo Candido,Basilio Pintaudi,Giovanni Targher
Nutrition, Metabolism and Cardiovascular Diseases.2020;30(10)1601
[DOI]
23RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020
Rajeev Chawla,S. V. Madhu,B. M. Makkar,Sujoy Ghosh,Banshi Saboo,Sanjay Kalra
International Journal of Diabetes in Developing Countries.2020;40(S1)1
[DOI]
24RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020
Rajeev Chawla,SV Madhu,BM Makkar,Sujoy Ghosh,Banshi Saboo,Sanjay Kalra
Indian Journal of Endocrinology and Metabolism.2020;24(1)1
[DOI]
25Sulfonylureas in the Current Practice of Type 2 Diabetes Management: Are They All the Same? Consensus from the Gulf Cooperation Council (GCC) Countries Advisory Board on Sulfonylureas
Yousef Al-Saleh,Shaun Sabico,Ahmed Al-Furqani,Amin Jayyousi,Dalal Alromaihi,Ebtesam Ba-Essa,Fatheya Alawadi,Juma Alkaabi,Mohamed Hassanein,Saud Al-Sifri,Seham Saleh,Thamer Alessa,Nasser M. Al-Daghri
Diabetes Therapy.2021;12(8)2115
[DOI]
26Real-world Evaluation of glycemic control and hypoglycemic Events among type 2 Diabetes mellitus study (REEDS): a multicentre, cross-sectional study in Thailand
Bancha Satirapoj,Thongchai Pratipanawatr,Boonsong Ongphiphadhanakul,Sompongse Suwanwalaikorn,Yupin Benjasuratwong,Wannee Nitiyanant
BMJ Open.2020;10(2)e031612
[DOI]
27Effect of Gliclazide or Gliclazide plus Metformin Combination on Glycemic Control in Patients with T2DM in India: A Real-World, Retrospective, Longitudinal, Observational Study from Electronic Medical Records
Nareen Krishna Polavarapu,Ravindra Kale,Bipin Sethi,R. K. Sahay,Uday Phadke,Santosh Ramakrishnan,Amey Mane,Suyog Mehta,Snehal Shah
Drugs - Real World Outcomes.2020;7(4)271
[DOI]
  Feedback 
  Subscribe 

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal